For cancer targeting gene therapy, the Grp78 promoter seems to be an ideal promoter to restrict expression of the therapeutic gene within the tumor tissue, and is, therefore, worthwhile a critical evaluation. This evidence concerns the gene HSPA5 and neoplasm.